rs796052056
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_017866.6(TMEM70):c.117_118dup(p.Ser40CysfsTer11) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000974 in 1,436,894 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 0.0000097 ( 0 hom. )
Consequence
TMEM70
NM_017866.6 frameshift
NM_017866.6 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 2.36
Genes affected
TMEM70 (HGNC:26050): (transmembrane protein 70) This gene likely encodes a mitochondrial membrane protein. The encoded protein may play a role in biogenesis of mitochondrial ATP synthase. Mutations in this gene have been associated with neonatal mitochondrial encephalocardiomyopathy due to ATP synthase deficiency. Alternatively spliced transcript variants have been described. [provided by RefSeq, Feb 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 8-73976397-C-CGT is Pathogenic according to our data. Variant chr8-73976397-C-CGT is described in ClinVar as [Pathogenic]. Clinvar id is 203989.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TMEM70 | NM_017866.6 | c.117_118dup | p.Ser40CysfsTer11 | frameshift_variant | 1/3 | ENST00000312184.6 | NP_060336.3 | |
TMEM70 | NM_001040613.3 | c.117_118dup | p.Ser40CysfsTer11 | frameshift_variant | 1/3 | NP_001035703.1 | ||
TMEM70 | NR_033334.2 | n.204_205dup | non_coding_transcript_exon_variant | 1/4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TMEM70 | ENST00000312184.6 | c.117_118dup | p.Ser40CysfsTer11 | frameshift_variant | 1/3 | 1 | NM_017866.6 | ENSP00000312599 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD3 exomes AF: 0.00000481 AC: 1AN: 207742Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 114818
GnomAD3 exomes
AF:
AC:
1
AN:
207742
Hom.:
AF XY:
AC XY:
0
AN XY:
114818
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000974 AC: 14AN: 1436894Hom.: 0 Cov.: 33 AF XY: 0.00000840 AC XY: 6AN XY: 714450
GnomAD4 exome
AF:
AC:
14
AN:
1436894
Hom.:
Cov.:
33
AF XY:
AC XY:
6
AN XY:
714450
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Mitochondrial complex V (ATP synthase) deficiency nuclear type 2 Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 20, 2023 | Variant summary: TMEM70 c.117_118dupGT (p.Ser40CysfsX11) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been associated with ATP synthase deficiency in HGMD. The variant allele was found at a frequency of 4.8e-06 in 207742 control chromosomes. c.117_118dupGT has been reported in the literature in individuals affected with Complex V Deficiency, Nuclear Type 2 (Cizkov_2008, Cameron_2011, etc). At least one publication reports reduction in ATP synthase activity in fibroblasts from a patient who was compound heterozygous for the variant and another known loss-of-function variant (Cameron_2011). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing;provider interpretation | Geisinger Autism and Developmental Medicine Institute, Geisinger Health System | Mar 23, 2017 | This 15 year old female with severe intellectual disability was found to carry a paternally inherited variant in the TMEM70 gene. She also carries a maternally inherited variant (p.Gly47Glu) in this gene, which is currently classified as a variant of uncertain significance. Previous biochemical analyses do not suggest that this patient has a mitochondrial deficiency. The p.Ser40CysfsX11 variant has been reported previously in the compound heterozygous state in an affected individual. The p.Ser40CysfsX11 variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Additionally, a pathogenic variant in MEF2C was identified in this patient. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 05, 2023 | This sequence change creates a premature translational stop signal (p.Ser40Cysfs*11) in the TMEM70 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TMEM70 are known to be pathogenic (PMID: 18953340, 21147908). For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 203989). This premature translational stop signal has been observed in individual(s) with TMEM70-related conditions (PMID: 18953340). This variant is present in population databases (rs765909414, gnomAD 0.003%). - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 2008 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centre for Mendelian Genomics, University Medical Centre Ljubljana | Mar 09, 2020 | This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PVS1,PS1_MOD,PM2. - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 20, 2017 | The c.117_118dupGT pathogenic variant in the TMEM70 gene has been reported previously in association with mitochondrial complex V deficiency an individual with psychomotor retardation, hypertrophic cardiomyopathy, lactic acidosis, methylglutaconic aciduria, and isolated deficiency of ATP synthase complex who was heterozygous for the c.117_118dupGT pathogenic variant and another pathogenic variant (CÃzková et al., 2008). The c.117_118dupGT variant causes a frameshift starting with codon Serine 40, changes this amino acid to a Cysteine residue, and creates a premature Stop codon at position 11 of the new reading frame, denoted p.Ser40CysfsX11. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The c.117_118dupGT variant was not observed in approximately 6,400 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. We interpret c.117_118dupGT as a pathogenic variant. - |
Mitochondrial proton-transporting ATP synthase complex deficiency Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 10, 2018 | The p.Ser40CysfsX11 variant in TMEM70 has been previously reported in at least 3 compound heterozygous individuals with ATP synthase deficiency, all of which al so carried the pathogenic c.317-2A>G variant (Cizkova 2008, Cameron 2011, Magner 2015). This variant has also been reported in ClinVar (Variation ID 203989) and has been identified in 3/107484 European chromosomes by the Genome Aggregation Database (gnomAD, http://gnomAD.broadinstitute.org). Functional studies provide some evidence that the p.Ser40CysfsX11 variant may impact protein function, by c ausing a reduction in ATP synthase activity (Cameron 2011). This variant is pred icted to cause a frameshift, which alters the protein?s amino acid sequence begi nning at position 40 and leads to a premature termination codon 11 amino acids d ownstream. This alteration is then predicted to lead to a truncated or absent pr otein. Biallelic loss of function of the TMEM70 gene has been associated with AT P synthase deficiency and related features, though this variant may be associate d with a milder phenotype after the neonate period (Honzik 2010, Magner 2015). I n summary, this variant meets criteria to be classified as pathogenic for isolat ed ATP synthase deficiency in an autosomal recessive manner. ACMG/AMP criteria a pplied: PVS1_Strong, PM3_Strong, PM2. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at